These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16033849)

  • 21. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
    J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M; Takahashi T; Yamamoto N; Koh Y
    J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
    Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
    Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
    Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
    Li H; Takayama K; Wang S; Shiraishi Y; Gotanda K; Harada T; Furuyama K; Iwama E; Ieiri I; Okamoto I; Nakanishi Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1297-305. PubMed ID: 25344762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
    Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K
    Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib: preclinical investigations.
    Hidalgo M
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):11-6. PubMed ID: 14682118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
    Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
    Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
    Hughes B; Mileshkin L; Townley P; Gitlitz B; Eaton K; Mitchell P; Hicks R; Wood K; Amler L; Fine BM; Loecke D; Pirzkall A
    Oncologist; 2014 Feb; 19(2):175-6. PubMed ID: 24457379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
    Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
    Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
    Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
    Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
    Herbst RS; Sandler A
    Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
    Wu Q; Li MY; Li HQ; Deng CH; Li L; Zhou TY; Lu W
    Acta Pharmacol Sin; 2013 Nov; 34(11):1427-36. PubMed ID: 24096601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erlotinib and bevacizumab have synergistic activity against melanoma.
    Schicher N; Paulitschke V; Swoboda A; Kunstfeld R; Loewe R; Pilarski P; Pehamberger H; Hoeller C
    Clin Cancer Res; 2009 May; 15(10):3495-502. PubMed ID: 19447871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
    DeFazio-Eli L; Strommen K; Dao-Pick T; Parry G; Goodman L; Winslow J
    Breast Cancer Res; 2011 Apr; 13(2):R44. PubMed ID: 21496232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.